Dide den Hollander

Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST)

Dide den Hollander, Winette T.A. van der Graaf, Ingrid M.E. Desar et al. · Acta Oncologica · 2019 · 34 citations · Full text

Medicine, Oncology, Pharmacology +15

Gastrointestinal Stromal Tumours (GIST) in Young Adult (18–40 Years) Patients: A Report from the Dutch GIST Registry

Nikki S. IJzerman, Cas Drabbe, Dide den Hollander et al. · Cancers · 2020 · 33 citations · Full text

Medicine, Oncology, Pathology +17

Unraveling the Heterogeneity of Sarcoma Survivors’ Health-Related Quality of Life Regarding Primary Sarcoma Location: Results from the SURVSARC Study

Ilse van Eck, Dide den Hollander, Vicky L. M. N. Soomers et al. · Cancers · 2020 · 31 citations · Full text

Medicine, Oncology, Cancer Survivorship Care +12

Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol

Dide den Hollander, Marco Fiore, Javier Martín‐Broto et al. · Cancers · 2020 · 30 citations · Full text

Medicine, Oncology, Cancer Rehabilitation +15

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data

Mahmoud Mohammadi, Nikki S. IJzerman, Dide den Hollander et al. · Targeted Oncology · 2023 · 16 citations · Full text

Medicine, Oncology, Pharmacotherapy +14